Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles,...
-
Upload
kathleen-wood -
Category
Documents
-
view
219 -
download
0
Transcript of Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles,...
![Page 1: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/1.jpg)
Buprenorphine: An Introduction
Walter Ling MD
Integrated Substance Abuse Programs
UCLALos Angeles, CA
April 21st 2006
www.uclaisap.org
![Page 2: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/2.jpg)
![Page 3: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/3.jpg)
Buprenorphine in the Treatment ofOpioid Addiction
• Buprenorphine as a medication– Development: Historical perspective– Pharmacology: Safety and efficacy
• Buprenorphine as a Treatment – Philosophical, societal and policy implications– The role of the clinicians
![Page 4: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/4.jpg)
![Page 5: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/5.jpg)
![Page 6: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/6.jpg)
![Page 7: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/7.jpg)
Classification of Addicts and Recommended Treatment
Types of Addicts• Correctional cases
• Mental defectives (degenerates)
• Social misfits
• Otherwise normal
Treatment• Internment camps
• Sterilization
• Vocational guidance
• Psychoanalysis
![Page 8: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/8.jpg)
Forty years later :Methadone
• Long acting
• Orally active opiate agonist capable of reducing or eliminating withdrawal signs and symptoms
• Reducing drug craving
• Normalizing physiological function
![Page 9: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/9.jpg)
![Page 10: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/10.jpg)
47%
23%
17%
12.5%
6%
0%
10%
20%
30%
40%
50%Not in Tx
Currently in Tx
In Tx 5 years
C&D
No needle use since admission to Tx
A B C D
The Effect of Methadone Treatments on HIV Seropositivity Rates
All subjects were male, heterosexual IV drug users in NYC. Treatment
provided was methadone maintenance.
Novick et al., Presented at CPDD, 1985
![Page 11: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/11.jpg)
Naltrexone
OOH O
N
OH
![Page 12: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/12.jpg)
Naltrexone: The Perfect Drug
• Orally Effective• Rapid onset of action• Long duration of action• Safe• Few side effects• Completely blocks effects of heroin• Non-addicting• No tolerance• No dependence• No withdrawal
![Page 13: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/13.jpg)
One reason not to take naltrexone:
Can’t get high!
![Page 14: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/14.jpg)
Naltrexone:The Perfect Drug “victimless cure”
It’s like taking nothing.
![Page 15: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/15.jpg)
The Opioid Receptor Family
![Page 16: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/16.jpg)
Potentially lethal dosePositive effect
=
addictive
potential
Negative effect
Full agonist -morphine/heroin
hydromorphone
Antagonist - naltrexone
dose
Antagonist + agonist/partial agonist
Agonist + partial agonist
Super agonist -fentanyl
Partial agonist - buprenorphine
Mu efficacy and opiate addictionMu efficacy and opiate addiction
![Page 17: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/17.jpg)
Buprenorphine as a Medication: Pharmacological Characteristics
Partial Agonist• high safety profile/ceiling effect
• low dependence
Tight Receptor Binding• long duration of action
• slow onset mild abstinence
![Page 18: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/18.jpg)
Good Effect
0
20
40
60
80
100
p 0.5 2 8 16 32
Buprenorphine (mg)
Pea
k S
core
3.75 15 60
Methadone (mg)
![Page 19: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/19.jpg)
Respiration
02468
1012141618
p 1 2 4 8 16 32
Buprenorphine (mg)
Bre
ath
s/m
inu
te
![Page 20: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/20.jpg)
Intensity of abstinence
60
50
40
30
20
10
0
Him
mel
sbac
h s
core
s
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Buprenorphine
Morphine
Days after drug withdrawal
![Page 21: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/21.jpg)
Study # 999A: Buprenorphine’sEffect on Opiate Use
0
5
10
15
20
25
% S
s W
ith
13
Con
secu
tive
Op
iate
Fre
e U
rin
es
Buprenorphine dose (mg)
1
4
8
16
![Page 22: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/22.jpg)
Buprenorphine Maintenance Treatment of Opiate Dependence: A Multicenter
Randomized Clinical Trial
![Page 23: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/23.jpg)
Mean Heroin Craving: 16 week completers
15
20
25
30
35
40
45
50
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Week of Study
Mea
n C
ravi
ng
Sco
re
1 mg
4 mg
8 mg
16 mg
![Page 24: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/24.jpg)
Joint Probability
N remaining in treatment
X
Total N of subjects
N giving drug free urinesN remaining in treatment
![Page 25: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/25.jpg)
Figure A: A Comparison of Buprenorphine doses from four studies using Joint Probability
0
10
20
30
40
50
Join
t P
roba
bili
ty S
core
Week 8 Week 17
Schottenfeld, et al. 1997 -4 mg
Johnson et al. 1992 - 8 mg
Ling et al. 1996- 8 mg
Strain et al. 1994 (8 variable)
Schottenfeld et al. 1997 -12 mg
![Page 26: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/26.jpg)
A Comparison of Methadone from Four Studies Using Joint Probability
0
10
20
30
40
50
60
70
80
Week 8 Week 17
ARC 20 mg
Schottenfeld 20 mg
LA 30 mg
Strain (50 variable)
ARC 60 mg
Schottenfeld 65 mg
LA 80 mg
![Page 27: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/27.jpg)
Buprenorphine Made Safer:Addition of Naloxone Reduces Abuse
• Naloxone will block buprenorphine’s effects by the IV but not the sublingual route
• Sublingual absorption of buprenorphine @ 70%; naloxone @ 10%
• If injected, BUP/NX will precipitate withdrawal in a moderately to severely dependent addict
![Page 28: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/28.jpg)
Buprenorphine made Safer:Buprenorphine/Naloxone Combination
4 part buprenorphine: 1 part naloxoneSublingual: Opiate agonist effect from
buprenorphine
Intravenous: Opiate antagonist effect from naloxone
Discourage IV use
Diminish street value
Diminish diversion
Allow for flexible dosing
![Page 29: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/29.jpg)
Buprenorphine as Treatment strategy:The First CTN Protocols
• Inpatient detoxification:– Buprenorphine/naloxone vs clonidine– (CTN 0001)
• Outpatient detoxification:– Buprenorphine/naloxone vs clonidine– (CTN 0002)
![Page 30: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/30.jpg)
Study Design
Buprenorphine/Naloxone13 days detoxification
Clonidine13 days detoxification
Open Randomized StudyBup/Nx:Clonidine = 2:1
![Page 31: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/31.jpg)
Joint Probability
N remaining in treatment
X
Total N of subjects
N giving drug free urinesN remaining in treatment
![Page 32: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/32.jpg)
Percent Present and Clean0001 (Inpatient)
0
10
20
30
40
50
60
70
80
90
100
Day 3 or 4 Day 7 or 8 Day 10 or 11 Day 13 or 14
ClonidineBup/Nx
![Page 33: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/33.jpg)
Percent Present and Clean0002 (Outpatient)
0
5
10
15
20
25
30
35
40
45
50
Day 3 or 4 Day 7 or 8 Day 10 or 11 Day 13 or 14
ClonidineBup/Nx
![Page 34: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/34.jpg)
NNT: Number Needed to TreatCTN 0001 (Inpatient)
• NNT for Bup/Nx 77/59 = 1.31 • NNT for Clonidine 36/8 = 4.5
NNT Clonidine : BupNx = 3.44
CTN 0002 (Outpatient)• NNT for Bup/Nx: 157/46 = 3.4 • NNT for Clonidine: 74/4 = 18.5
NNT Clonidine : Bup/Nx = 5.44
NNT= Number of patients needed to treat to achieve 1 treatment success
![Page 35: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/35.jpg)
Drug Addiction Treatment Act of 2000 An Amendment to the Controlled Substances Act
(October, 2000)
• Subutex and Suboxone approved October 8, 2002 and marketed in January 2003
• Qualified physicians can treat up to 30 patients with the Buprenorphine products ( sublingual tablets)
• Physicians become qualified by training in sessions from designated organizations- APA, ASAM, AAAP, or over the internet; or if otherwise qualified
• Physicians can treat patients in their usual medical practice setting; able to provide or refer for psychosocial treatment.
![Page 36: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/36.jpg)
Our Treatment Philosophy
Addicts are sick; they need help
They also sin; don’t treat them too well
![Page 37: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/37.jpg)
Treatment of Opiate Dependence
• Detoxification
• Maintenance
![Page 38: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/38.jpg)
![Page 39: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/39.jpg)
![Page 40: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/40.jpg)
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12
In Treatment
Rate
28.9%
Months Since Drop Out
1-3Months
Later
4-6Months
Later
45.5%
57.6%
72.7%
82.1%
7-9Months
Later
10-12Months
Later
Ball, JC, Ross A. The Effectiveness of Methadone Maintenance Treatment, Springer-Verlag, New York, 1991
Pe
rce
nt
IV U
se
rs
Relapse to IV Drug Use After Termination of Methadone Maintenance Treatment
![Page 41: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/41.jpg)
Detoxification
Detoxification is good for a lot of things; staying off drugs is not one of them.
![Page 42: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/42.jpg)
Pharmacotherapy and Recovery
• “Medication is not recovery”?
• Addiction is chemistry went wrong
• You can change the brain with experience or with medication; they are the same thing
![Page 43: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/43.jpg)
How People Change
• “You can change the brain with biological treatment or with behavioral treatment”
• Alan Leshner, Former head NIDA
• “You can change someone’s life by altering his genes; but you also do that by paying off his credit card”
• James Watson
![Page 44: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/44.jpg)
Summary: Will Buprenorphine be a Success?
• Not a new medication but a vehicle for a new treatment philosophy
• Not just to change patients but to change us
• New attitude from community leaders like us should lead to new societal attitude towards addiction and change the way we treat and view those afflicted
![Page 45: Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu .](https://reader035.fdocuments.in/reader035/viewer/2022062309/56649e965503460f94b9a0fa/html5/thumbnails/45.jpg)
Thanks to
National Institute on Drug Abuse
NIDA Clinical Trials Network Staff
CTN Publications Committee
Participating CTN Nodes and CTPs
Reckitt Benckiser
Participating Patients
You the audience